Solvay’s Zeniva® PEEK Enables Breakthrough Intervertebral Joint Fusion Technology from Vertera Spine
Zeniva® PEEK’s superior toughness contributed to a novel porous surface technology that forms a more durable and cost-effective fusion site than conventional metal coatings
ALPHARETTA, Ga., Oct. 14, 2015 – Solvay Specialty Polymers, a leading global supplier of high-performance polymers, announced today that Vertera Spine, a pioneer in advanced functional surface technologies for spine applications, chose its Zeniva® polyetheretherketone (PEEK) polymer to develop PEEK Scoria™, a novel porous surface technology for stable, cost-effective intervertebral joint fusion. The porous character of Vertera Spine’s biomaterial facilitates integration of bone tissue with the company’s COHERE™ Cervical Interbody Fusion Device. Offering excellent biocompatibility, toughness and fatigue resistance, as well as a modulus very similar to bone, Zeniva® PEEK proved to be a key enabler for this breakthrough medical device. Both companies are showcasing the technology at Solvay’s booth (#1483) during the North American Spine Society (NASS) meeting in Chicago, from Oct. 14 to 17.
Backed by extensive research at Duke University and the Georgia Institute of Technology, Vertera Spine’s PEEK Scoria™ innovation represents a significant leap forward in how surface treatments are applied to intervertebral joint fusion devices. Where conventional approaches coat the fusion device, this surface treatment is grown directly from the bulk PEEK material that comprises Vertera Spine’s COHERE™ system. Solvay’s Zeniva® PEEK comprises both the porous surface technology and the device on which it is grown.
“Given the fast-changing economics of healthcare, we developed PEEK Scoria™ to address growing clinical demand for fusion devices that integrate more effectively with bone at a cost-competitive price point,” said Chris Lee, co-founder and CEO of Vertera Spine. “The superior toughness of Solvay’s Zeniva® PEEK was critical to our success. The seamless interface it enabled between the porous and bulk materials is more durable than metal coatings and yet two times stronger in shear than trabecular bone. Solvay’s material and industry expertise helped our COHERE™ device to become the first fusion system made out of porous PEEK to receive 510(k) clearance from the U.S. Food and Drug Administration.”
By growing PEEK Scoria™ directly onto the device, Vertera Spine eliminated the need for additive materials, which significantly lowered the manufacturing costs of its device vs. metal-coated implants. This makes its COHERE™ solution competitive with current PEEK device offerings and more cost effective than titanium-coated fusion devices.
“Vertera Spine’s novel porous surface layer may change the game in how future PEEK-based intervertebral joint fusion devices integrate with bone,” said Maria Gallahue-Worl, global business development manager for Healthcare at Solvay Specialty Polymers. “Also, neither the porosity of PEEK Scoria™ nor its growth onto bulk polymer is something you can achieve easily with metal solutions or even with many competitive resins. In many ways, this makes Vertera Spine’s application emblematic of the incredible potential that Solvay’s comprehensive line of biomaterials holds for the future of implantable medical device innovation, and it further illustrates the growing momentum behind our advanced materials portfolio.”
The porous features of the PEEK Scoria™ surface technology are specifically engineered to facilitate bone tissue in-growth. The surface material features 300-µm average pore size, layer thicknesses greater than 500 µm, over 99 percent interconnectivity and a wettable surface. Pre-clinical testing indicates that bone can infiltrate within these pores and form direct contact with the PEEK Scoria™ surface, which improves how PEEK devices interact with bone.
In addition, because Vertera Spine’s COHERE™ device and PEEK Scoria™ surface treatment are uniformly comprised of Solvay’s Zeniva® PEEK, the technology will not generate visual artifacts when medical imaging is applied, allowing surgeons to easily assess the fusion site.
Solvay’s Zeniva™ PEEK is part of its Solviva® Biomaterials portfolio, which is offered for use in implantable medical devices. The biomaterial boasts a modulus very close to that of cortical bone plus excellent biocompatibility, toughness, and fatigue resistance.
™ COHERE and Scoria are trademarks Vertera Spine
Solvay Specialty Polymers manufactures over 1500 products across 35 brands of high-performance polymers – fluoropolymers, fluoroelastomers, fluorinated fluids, semi-aromatic polyamides, sulfone polymers, aromatic ultra-high performance polymers, high barrier polymers and cross-linked high-performance compounds – for use in Aerospace, Alternative Energy, Automotive, Healthcare, Membranes, Oil and Gas, Packaging, Plumbing, Semiconductors, Wire & Cable, and other industries. Learn more at www.solvayspecialtypolymers.com.
Solvay is a multi-specialty chemical company, committed to developing chemistry that addresses key societal challenges. Solvay innovates and partners with customers in diverse global end markets. Its products and solutions are used in planes, cars, smart and medical devices, batteries, in mineral and oil extraction, among many other applications promoting sustainability. Its lightweighting materials enhance cleaner mobility, its formulations optimize the use of resources and its performance chemicals improve air and water quality. Solvay is headquartered in Brussels with around 27,000 employees in 58 countries. Net sales were € 10.9 billion in 2016, with 90% from activities where Solvay ranks among the world’s top 3 leaders. Solvay SA (SOLB.BE) is listed on Euronext Brussels and Paris (Bloomberg: SOLB.BB - Reuters: SOLB.BR) and in the United States its shares (SOLVY) are traded through a level-1 ADR program.
Vertera Spine is a privately held medical device company working to develop and commercialize a portfolio of surgical solutions that use or complement its patented porous surface technology to address critical clinical needs in spine procedures. The company has received grant funding from the National Science Foundation and Georgia Research Alliance to translate its growing technology portfolio into commercial products. For more information, visit www.verteraspine.com.